Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Concateno wins Italian road police deal

This article was originally published in Clinica

Executive Summary

UK drug and alcohol testing specialist Concateno has won a contract to supply the road police in northern Italy with the Cozart drug detection system (DDS). The deal, part of an anti-drug driving campaign that will run until the end of 2007 in the Piedmont and Valle d'Aosta region, will see police officers using the DDS to perform roadside tests on drivers for heroin, cocaine, cannabis, amphetamine, methamphetamine and benzodiazepines. The test analyses a non-invasive saliva sample and produces the results in less than five minutes, according to Concateno. Piedmont police said that this collaboration will help it document the amount of incidents related to driving under the influence of drugs to a level similar to that of drink-driving testing. Concateno obtained the DDS through its acquisition of Cozart in August 2007 (see Clinica No 1273, p 13).

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT050101

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel